Patients who received nipocalimab 15 mg/kg demonstrated a greater than 70 percent relative average improvement on the primary endpoint compared to patients who received placebo
Sjögren's disease is a chronic, debilitating, and prevalent autoantibody disease with no approved advanced treatments
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.